Cover Image
市場調查報告書

市場進入的課題:多發性硬化症 (美國)

Market Access Impact: Multiple Sclerosis (US) 2017

出版商 FirstWord 商品編碼 372768
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
市場進入的課題:多發性硬化症 (美國) Market Access Impact: Multiple Sclerosis (US) 2017
出版日期: 2017年07月01日 內容資訊: 英文
簡介

本報告依據以美國的100名神經科醫生的多發性硬化症治療藥的處方趨勢的調查結果,提供主要10項品牌藥的市場佔有率的影響因素,各個產品的進入市場的妨礙要素、障礙等彙整資料。

調查課題

  • 進入市場的各種障礙
    • 醫生最大量開立處方的品牌是?
    • 受到各種障礙影響的處方箋數是?
    • 哪個障礙影響最大?
  • 各品牌的障礙的影響
    • 開立各品牌處方的醫生數是?沒打算開立處方數是?
    • 不開立處方的理由是?替代處方是?
    • 各品牌的市場佔有率是?

調查對象

  • Aubagio (teriflunomide; Genzyme)
  • Avonex (interferon beta-1a; Biogen)
  • Betaseron (interferon beta-1b; Bayer)
  • Copaxone (glatiramer acetate; Teva)
  • Gilenya (fingolimod; Novartis)
  • Lemtrada (alemtuzumab; Genzyme)
  • Plegridy (peginterferon beta-1a; Biogen)
  • Rebif (interferon beta-1a; EMD Serono)
  • Tecfidera (dimethyl fumarate; Biogen)
  • Tysabri (natalizumab; Biogen)

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

New products suffer from market access barriers, as established therapies reap the spoils

Despite prescribing rates for many of the leading treatments for multiple sclerosis in the US being healthy, market barriers affect nearly 1 in 5 prescriptions. This isn't all bad news for some brands, but others are losing out on market share gains. One of the new kids on the block could get a market share bump of over 100% if neurologists could prescribe it instead of its competitors.

Market Access Impact: Multiple Sclerosis (US) shows you how 7 barriers affect your market share, revealing how much you win and lose, who you take share from, and who gets your lost share.

Based on a survey of 100 US-based neurologists, the report covers 12 major therapies from Genzyme, Biogen, Bayer, Teva, Sanofi, Novartis, Roche, EMD Serono, and AbbVie/Biogen.

Not your market? Click here to see the EU5 report

Top Takeaways

  • Barriers affect just under 20% of prescriptions. The three biggest barriers that account for over half of this impact are a mix of market access and patient related barriers.
  • One brand sees an impressive market share gain. Patient-preference plays a significant role in this gain, suggesting other treatments just aren't meeting the mark.
  • Most brands gain: 7 out of the 12 surveyed brands see a net market share gain, with many of these gains modest to almost non-existent.
  • Lots of brands are widely prescribed. 8 out of 12 brands are prescribed by over three quarters of neurologists, and many of them are also willing to consider brands they don't prescribe.
  • Time on market and safety seem to drive the number of barriers experienced per brand. New arrivals and treatments which have poor safety profiles experience the most barriers, with one of these experiencing 4 separate barriers.
  • Awareness is good for all brands. Very few neurologists haven't heard of the brands we surveyed, but 'willingness to try' data might be surprising for some brands.

Insight into 12 Major Asthma/COPD Drugs

  • Aubagio (teriflunomide; Sanofi)
  • Avonex (interferon beta-1a; Biogen)
  • Betaseron (interferon-beta-1; Bayer)
  • Copaxone (glatiramer acetate; Teva)
  • Gilenya (fingolimod; Novartis)
  • Lemtrada (alemtuzumab; Genzyme)
  • Ocrevus (ocrelizumab; Roche)
  • Plegridy (peginterferon beta-1a; Biogen)
  • Rebif (interferon beta-1a; EMD Serono)
  • Tecfidera (dimethyl fumarate; Biogen)
  • Tysabri (natalizumab; Biogen)
  • Zinbryta (daclizumab; AbbVie/Biogen)

Exploring Market Access Barriers

Market Access Impact: Multiple Sclerosis (US) explores key issues affecting drug manufacturers. You'll learn:

How barriers affect market access:

  • What brands do doctors prescribe the most?
  • How many prescriptions do barriers affect?
  • Which barriers have the biggest impact?

How barriers affect your brand:

  • How many doctors prescribe your brand? How many don't, but would consider it?
  • Why don't doctors prescribe your brand? What do they prescribe instead?
  • Which competing brands does your brand take market share from?

A Report Based on Expert Knowledge

We surveyed 100 US-based neurologists, chosen from the largest community of validated physicians in the world.

All respondents have:

  • Been practicing for 2+ years
  • Prescribed at least one of the listed products
  • Seen at least 5 patients with asthma and/or COPD in total in the last month

We conducted the survey between July 3rd and 13th, 2017.

MONEY BACK GUARANTEE!

At FirstWord, we stand behind our reports. If you're not completely satisfied, we'll refund your money. Guaranteed.

About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company's success.

FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Table of Contents

1.What are market barriers?

2.About this report

3.About the survey

4.Brands included in the survey

5.Executive summary

Back to Top